Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
Authors' conclusion
Over the last 15-year period, obesity has reached epidemic levels in US youth and adults with T1D, with significant disparities among racial and ethnic minoritized populations. These findings, coupled with the increase in GLP-1RA prescriptions, underscore the urgent need for data on GLP-1RAs' safety and effectiveness and guidance for obesity management in T1D.
Study context
- Population
- US youth (2–19 years) and adults (≥20 years) with T1D identified by a validated algorithm, 2008 to 2023
- Exposure
- Trends from 2008-2011 to 2020-2023
- Outcome
- Trends in obesity and GLP-1 RA prescriptions across BMI categories
- Follow-up
- 2008-2011 to 2020-2023
Methodological detailsde-identified EHR data, 33 US health systems
- De-identified EHR data
- 33 US health systems
Main finding
As reported in the abstract
Prevalence of obesity among youth with T1D
P for trend < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | 2008-2011 | 2020-2023 | P value |
|---|---|---|---|
| Prevalence of obesity among adults with T1D | 30.5% (CI 30.0%–31.0%) | 38.1% (CI 37.8%–38.5%) | P for trend < 0.001 |
Obesity by race and ethnicity
- Obesity was highest in Black and Hispanic youth and adults; racial and ethnic disparities persisted over time
GLP-1 RA prescriptions · last 15-year period
- GLP-1 RA prescriptions significantly increased across all body mass index (BMI) categories in a dose-response manner among youth and adults with T1D
- all p-for-trend < 0.001
Original publication
Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States. Diabetes Obes Metab. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →